PURPOSE: The purpose of this study was to determine if non-specific COX inhibition could extend pore lifetime in hairless guinea pigs following microneedle treatment. METHODS: Hairless guinea pigs were treated with microneedle arrays ± daily application of Solaraze® gel (3% diclofenac sodium (non-specific COX inhibitor) and 2.5% hyaluronic acid); transepidermal water loss was utilized to evaluate pore lifetime. To examine the permeation of naltrexone, additional guinea pigs were treated with microneedles ± daily Solaraze® gel followed by application of a 16% transdermal naltrexone patch; pharmacokinetic analysis of plasma naltrexone levels was performed. Histological analysis was employed to visualize morphological changes following microneedle and Solaraze® treatment. RESULTS: Animals treated with microneedles + Solaraze® displayed extended pore lifetime (determined by transepidermal water loss measurements) for up to 7 days. Enhanced naltrexone permeation was also observed for an extended amount of time in animals treated with microneedles + Solaraze®. No morphological changes resulting from microneedle treatment or COX inhibition were noted. CONCLUSIONS: Non-specific COX inhibition is an effective means of extending pore lifetime following microneedle treatment in hairless guinea pigs. This may have clinical implications for extending transdermal patch wear time and therefore increasing patient compliance with therapy.
PURPOSE: The purpose of this study was to determine if non-specific COX inhibition could extend pore lifetime in hairless guinea pigs following microneedle treatment. METHODS: Hairless guinea pigs were treated with microneedle arrays ± daily application of Solaraze® gel (3% diclofenac sodium (non-specific COX inhibitor) and 2.5% hyaluronic acid); transepidermal water loss was utilized to evaluate pore lifetime. To examine the permeation of naltrexone, additional guinea pigs were treated with microneedles ± daily Solaraze® gel followed by application of a 16% transdermal naltrexone patch; pharmacokinetic analysis of plasma naltrexone levels was performed. Histological analysis was employed to visualize morphological changes following microneedle and Solaraze® treatment. RESULTS: Animals treated with microneedles + Solaraze® displayed extended pore lifetime (determined by transepidermal water loss measurements) for up to 7 days. Enhanced naltrexone permeation was also observed for an extended amount of time in animals treated with microneedles + Solaraze®. No morphological changes resulting from microneedle treatment or COX inhibition were noted. CONCLUSIONS: Non-specific COX inhibition is an effective means of extending pore lifetime following microneedle treatment in hairless guinea pigs. This may have clinical implications for extending transdermal patch wear time and therefore increasing patient compliance with therapy.
Authors: Satyanarayana Valiveti; Buchi N Nalluri; Dana C Hammell; Kalpana S Paudel; Audra L Stinchcomb Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2004-10-25 Impact factor: 3.205
Authors: Dana C Hammell; Mohamed Hamad; Haranath K Vaddi; Peter A Crooks; Audra L Stinchcomb Journal: J Control Release Date: 2004-06-18 Impact factor: 9.776
Authors: Wijaya Martanto; Shawn P Davis; Nicholas R Holiday; Jenny Wang; Harvinder S Gill; Mark R Prausnitz Journal: Pharm Res Date: 2004-06 Impact factor: 4.200
Authors: Stan L Banks; Raghotham R Pinninti; Harvinder S Gill; Kalpana S Paudel; Peter A Crooks; Nicole K Brogden; Mark R Prausnitz; Audra L Stinchcomb Journal: J Pharm Sci Date: 2010-07 Impact factor: 3.534
Authors: Mikolaj Milewski; Kalpana S Paudel; Nicole K Brogden; Priyanka Ghosh; Stan L Banks; Dana C Hammell; Audra L Stinchcomb Journal: Mol Pharm Date: 2013-09-23 Impact factor: 4.939
Authors: Ali Aghazadeh-Habashi; Yang Yang; Kathy Tang; Raimar Lőbenberg; Michael R Doschak Journal: Drug Deliv Transl Res Date: 2015-12 Impact factor: 4.617